creators_name: Ding, C
creators_name: Xu, J
creators_name: Li, J
creators_id: chding@utas.edu.au
creators_id: 
creators_id: 
type: article
datestamp: 2008-06-11 03:56:10
lastmod: 2008-07-18 11:00:03
metadata_visibility: show
title: ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.
ispublished: pub
subjects: 320503
full_text_status: restricted
note: Changhai Ding
abstract: ABT-874, a fully human mAb that blocks the binding of IL-12 and IL-23 to their shared IL-12 receptor beta1, is currently being developed by Abbott Laboratories for the potential treatment of Crohn's disease and psoriasis. The compound is currently in phase III clinical trials for psoriasis and phase II trials for Crohn's disease. ABT-87 was previously being developed for the potential treatment of multiple sclerosis; however, by May 2007, development for this indication was discontinued.
date: 2008-05
date_type: published
publication: Current Opinion in Investigational Drugs
volume: 9
number: 5
pagerange: 515-522
refereed: TRUE
issn: 1472-4472
official_url: http://www.biomedcentral.com/1472-4472/9/515
citation: Ding, C and Xu, J and Li, J (2008) ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Current Opinion in Investigational Drugs, 9 (5). pp. 515-522. ISSN 1472-4472
document_url: http://eprints.utas.edu.au/6553/1/ABT-874.pdf